Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.

Joyce Hoi-Sze YouXinchan JiangWally H LeePaul K S ChanSiew C Ng

Published in: Journal of gastroenterology and hepatology (2020)

FMT for IBD patients with RCDI appeared to save both direct medical cost and QALYs when comparing to vancomycin (with or without bezlotoxumab) and fidaxomicin.

Keyphrases

patients with inflammatory bowel disease
clostridium difficile
healthcare
methicillin resistant staphylococcus aureus
cell therapy
ulcerative colitis
stem cells
mesenchymal stem cells